From ARC-HBR and PRECISE-DAPT to PRECISE-2: Development and Validation of a Novel Universal Bleeding Risk Score

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

• Consultant Fee/Honoraria/Speaker's Bureau - Terumo Medical Corporation; Daiichi-Sankyo/Elil Lilly and Company; AstraZenca; Biotronik; Chiesi; Abbott; Cordis Corporation, a Johnson & Johnson company; Novartis, Vesalio, Om Pharma (grant or contract support), Alvimedica; Concept Medical
• Grant Support/Research Contract - Concept Medical